Xeltis announced favorable outcomes from its EU clinical trial evaluating Xabg, an innovative coronary artery bypass graft made from bioresorbable materials that regenerate into living tissue. Utilizing supramolecular chemistry and nanofiber electrospinning, Xabg offers a restorative vascular solution transitioning from synthetic scaffold to endogenous vessel. These results mark a significant step toward next-generation cardiovascular implants with enhanced longevity and functionality.